Navtemadlin is an MDM2 inhibitor that can help to kill cancer cells by boosting the activity of p53, a protein that controls cell growth and induces cell death in response to DNA damage.

The BOREAS study investigated navtemadlin, an MDM2 inhibitor, in people with myelofibrosis. MDM2 inhibitors help increase levels of the tumor-suppressing protein p53, which helps stop abnormal ...

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

In this video, John O. Mascarenhas, MD, professor of medicine at the Icahn School of Medicine, discussed recent developments and emerging treatments in myeloproliferative neoplasms care.

Researchers from the University of Houston and Baylor College of Medicine presented preclinical data for MA-242, a dual inhibitor of MDM2 and NFAT1, being developed for the treatment of cancer.

an oral small molecule inhibitor of the MDM2-p53 protein-protein interactions to treat solid tumors and hematological malignancies; and APG-1252, a small molecule drug to restore apoptosis through ...

As MDM2 is a negative regulator of p53 ... Consequently, BI 907828 and immune checkpoint inhibitors targeting PD-1 may show synergistic activity in combination. Based on encouraging preclinical ...

ARF increases p53 levels by sequestering MDM2, which facilitates the degradation ... Among the p53 target genes are WAF1, an inhibitor of cyclin-dependent protein kinases (CDKs) that, among ...